Multicenter study for the correlation among PD-L1 antibodies, tumor mutation burden (TMB) and lung immune prognostic index (lipi) in Chinese patients with advanced lung adenocarcinoma
机构：[1]Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China[2]Peking Union Med Coll, Beijing, Peoples R China[3]Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China[4]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[5]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[6]Hebei Med Univ, Fourth Hosp, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院病理科医技科室
Ying Jianming,Yuan Pei,Li Yuan,et al.Multicenter study for the correlation among PD-L1 antibodies, tumor mutation burden (TMB) and lung immune prognostic index (lipi) in Chinese patients with advanced lung adenocarcinoma[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.e21218.
APA：
Ying, Jianming,Yuan, Pei,Li, Yuan,Jiang, Lili,Liu, Yueping&Li Junling.(2018).Multicenter study for the correlation among PD-L1 antibodies, tumor mutation burden (TMB) and lung immune prognostic index (lipi) in Chinese patients with advanced lung adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Ying, Jianming,et al."Multicenter study for the correlation among PD-L1 antibodies, tumor mutation burden (TMB) and lung immune prognostic index (lipi) in Chinese patients with advanced lung adenocarcinoma".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)
医学